OAP V is expected to provide mainly growth capital to between 20 and 25 health care companies across the biopharma, medical technology, health care services, diagnostics, and distribution subsectors.
Investment sizes will typically range from $10 million to $50 million per company.
Bagaimana tanggapan anda mengenai artikel ini?
“ADB’s investment in OAP V advances its efforts to mobilize private sector financing for long-term health care solutions in developing Asia,” said ADB Private Sector Investment Funds and Special Initiatives Division Director Janette Hall in a press release on Monday.
“Greater health care capacity is more important than ever as we recover from the pandemic, which has also exposed the need for more innovative services and digital health technologies,” Hall added.
This is ADB’s fourth investment in an OrbiMed-managed health care fund, following previous commitments in OrbiMed Asia Partners II, LP in 2014, OrbiMed Asia Partners III, LP in 2017, and OrbiMed Asia Partners II, LP in 2021.
“OAP V is expected to deliver effective and sustainable health care solutions and to support research and development in disease detection and vaccine production,” said Hall.
Health care is one of the fastest-growing sectors in India and the PRC, driven by demand from a growing middle class. Health care expenditure per capita in both countries increased by more than 5% annually during 2009–2019.
OrbiMed is a leading global health care investment firm, with about $17 billion in assets under management across a range of private equity funds, public equity funds, and private credit and royalty funds. OrbiMed invests across the health care industry, from start-ups to large multinational corporations, providing tailored financing solutions and extensive global team resources to help build world-class health care companies.
(WAH)
Artikel ini bersumber dari www.medcom.id.